New therapeutic options became available in 2015 in the European Union. We present the availability of interferon-free regimens with direct acting antivirals (DAA) in four Central European countries - the Czech Republic, Hungary, Poland and Slovakia - which despite similar historical, geographical and economic situations demonstrate different systems for access to anti-HCV (hepatitis C virus) medication. Treatment of patients in the Czech Republic was based in 2015 on an exceptional individual reimbursement procedure, but regular reimbursement procedures are expected in 2016. In Hungary the decision for treatment is balanced against budget limitations and the national Priority Index system reflecting stage of liver disease, activity of the disease and predictive factors. A reimbursed interferon (IFN)-free therapeutic program for all genotypes, without restrictions related to hepatic fibrosis and treatment history, is already available in Poland. In Slovakia patients with advanced fibrosis are currently selected for possible IFN-free therapy in 2016.

Center for Gastroenterology and Hepatology THALION Bratislava Slovakia

Department of Infectious Diseases and Hepatology Medical University of Bialystok Bialystok Poland

Department of Internal Medicine 1 Faculty of Medicine Charles University and Central Military Hospital Prague Prague Czech Republic

Department of Internal Medicine University Hospital an UPJS Medical Faculty Kosice Slovakia

Department of Medicine Military Hospital Medical Centre Hungarian Defence Forces Budapest Hungary

United Saint Istvan and Saint Laszlo Hospital Saint Laszlo Hospital Outpatient Clinic Budapest Hungary

Zobrazit více v PubMed

Urbánek P, Husa P, Šperl J, et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C. Gastroent Hepatol. 2015;69:455–471.

EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236. PubMed

Hungarian Hepatitis Registry. available from: www.hepreg.hu.

Hunyady B, Gerlei Z, Gervain J, et al. Hungarian Hepatitis Therapeutic Committee. Budapest: National Consensus Guideline; 2015. Sep 12,

Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide – filling the gaps. J Viral Hepatitis. 2015;22(Suppl 1):1–5. PubMed

Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Efficacy and safety of paritaprevir/r/ombitasvir/dasabuvir +/- ribavirin in genotype 1 HCV infected patients treated in real life settings (AMBER study) J Viral Hepatitis. 2015;22(Suppl 3):4.

Flisiak R, Halota W, Tomasiewicz K, et al. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastro Hepatol. 2015;27:70–76. PubMed

Schréter I, Kristian P, Klement C, et al. Prevalence of hepatitis C virus infection in Slovakia. Klin Mikrobiol Infekc Lek. 2007;13:54–58. PubMed

Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol. 2013;59:434–441. PubMed